142 related articles for article (PubMed ID: 18549972)
1. Fluorine magnetic resonance in vivo: a powerful tool in the study of drug distribution and metabolism.
Reid DG; Murphy PS
Drug Discov Today; 2008 Jun; 13(11-12):473-80. PubMed ID: 18549972
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole.
Schneider E; Bolo NR; Frederick B; Wilkinson S; Hirashima F; Nassar L; Lyoo IK; Koch P; Jones S; Hwang J; Sung Y; Villafuerte RA; Maier G; Hsu R; Hashoian R; Renshaw PF
J Clin Pharm Ther; 2006 Jun; 31(3):261-73. PubMed ID: 16789992
[TBL] [Abstract][Full Text] [Related]
3. Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy.
van Laarhoven HW; Punt CJ; Kamm YJ; Heerschap A
Crit Rev Oncol Hematol; 2005 Dec; 56(3):321-43. PubMed ID: 15982898
[TBL] [Abstract][Full Text] [Related]
4. [Fluorine-19 nuclear magnetic resonance spectroscopy: a privileged tool for the study of the metabolism and pharmacokinetics of fluoropyrimidines].
Malet-Martino MC; Martino R; Armand JP
Bull Cancer; 1990; 77(12):1223-44. PubMed ID: 2081282
[TBL] [Abstract][Full Text] [Related]
5. Challenges for drug studies in children: CYP3A phenotyping as example.
de Wildt SN; Ito S; Koren G
Drug Discov Today; 2009 Jan; 14(1-2):6-15. PubMed ID: 18721895
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical applications of magnetic resonance imaging (MRI).
Richardson JC; Bowtell RW; Mäder K; Melia CD
Adv Drug Deliv Rev; 2005 Jun; 57(8):1191-209. PubMed ID: 15935869
[TBL] [Abstract][Full Text] [Related]
7. In vivo 19F MR imaging and spectroscopy for the BNCT optimization.
Porcari P; Capuani S; D'Amore E; Lecce M; La Bella A; Fasano F; Migneco LM; Campanella R; Maraviglia B; Pastore FS
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S365-8. PubMed ID: 19375924
[TBL] [Abstract][Full Text] [Related]
8. Detection of (19)F-labeled biopharmaceuticals in cell cultures with magnetic resonance.
Bartusik D; Tomanek B
Adv Drug Deliv Rev; 2013 Jul; 65(8):1056-64. PubMed ID: 23603212
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance spectroscopy applied to clinical oncology.
Leach MO
Technol Health Care; 1994 Dec; 2(4):235-46. PubMed ID: 7842308
[TBL] [Abstract][Full Text] [Related]
10. Trifluoromethoxy-benzylated ligands improve amyloid detection in the brain using (19)F magnetic resonance imaging.
Amatsubo T; Morikawa S; Inubushi T; Urushitani M; Taguchi H; Shirai N; Hirao K; Kato M; Morino K; Kimura H; Nakano I; Yoshida C; Okada T; Sano M; Tooyama I
Neurosci Res; 2009 Jan; 63(1):76-81. PubMed ID: 18996420
[TBL] [Abstract][Full Text] [Related]
11. First
Starke L; Millward JM; Prinz C; Sherazi F; Waiczies H; Lippert C; Nazaré M; Paul F; Niendorf T; Waiczies S
Theranostics; 2023; 13(4):1217-1234. PubMed ID: 36923535
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive mapping of lipids in plant tissue using magnetic resonance imaging.
Neuberger T; Rolletschek H; Webb A; Borisjuk L
Methods Mol Biol; 2009; 579():485-96. PubMed ID: 19763491
[TBL] [Abstract][Full Text] [Related]
13. Fluorine in pharmaceuticals: looking beyond intuition.
Müller K; Faeh C; Diederich F
Science; 2007 Sep; 317(5846):1881-6. PubMed ID: 17901324
[TBL] [Abstract][Full Text] [Related]
14. Tumor models and specific contrast agents for small animal imaging in oncology.
Ni Y; Wang H; Chen F; Li J; DeKeyzer F; Feng Y; Yu J; Bosmans H; Marchal G
Methods; 2009 Jun; 48(2):125-38. PubMed ID: 19328231
[TBL] [Abstract][Full Text] [Related]
15. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
Zolnik BS; Sadrieh N
Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging in the evaluation of acute stroke.
Olivot JM; Marks MP
Top Magn Reson Imaging; 2008 Oct; 19(5):225-30. PubMed ID: 19512854
[TBL] [Abstract][Full Text] [Related]
17. [Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis].
Sailer M; Fazekas F; Gass A; Kappos L; Radue EW; Rieckmann P; Toyka K; Wiendl H; Bendszus M
Rofo; 2008 Nov; 180(11):994-1001. PubMed ID: 18937154
[TBL] [Abstract][Full Text] [Related]
18. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
[TBL] [Abstract][Full Text] [Related]
19. Characterization of scaffolds for tissue engineering by benchtop-magnetic resonance imaging.
Nitzsche H; Metz H; Lochmann A; Bernstein A; Hause G; Groth T; Mäder K
Tissue Eng Part C Methods; 2009 Sep; 15(3):513-21. PubMed ID: 19191523
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of fluorine-containing drugs.
Park BK; Kitteringham NR; O'Neill PM
Annu Rev Pharmacol Toxicol; 2001; 41():443-70. PubMed ID: 11264465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
